Vaccine giant Sanofi (SNY) Pasteur has quietly pulled the plug on its Zika vaccine project, a move that underscores how difficult it may be at this stage to develop a vaccine against the virus.

The company announced the move in a statement posted on its website at 3 p.m. Friday, pointing to a decision by a federal funding body to scale back spending on Zika-related research. Sanofi said BARDA — the Biomedical Advanced Research and Development Authority, an arm of the Department of Health and Human Services — informed the company in mid-August that it was reducing its financial assistance for Sanofi’s Zika vaccine project.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy